Literature DB >> 25142531

Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature.

R V Lukas1, N A Mata-Machado2, M K Nicholas1,3,4, R Salgia5, T Antic6, V M Villaflor5.   

Abstract

The aim of this study was to more clearly define the clinical course of leptomeningeal carcinomatosis due to esophageal cancer. A single institution retrospective case series was conducted. Additionally, a systematic review of the literature was performed. We present a large case series (n = 7) of leptomeningeal carcinomatosis due to esophageal cancer. Our case series and systematic review of the literature report similar findings. In our series, we report a predominance of male patients (86%) with adenocarcinoma histology (77%). Variable onset of leptomeningeal involvement of esophageal cancer in relation to the original diagnosis of the primary disease (5 months to 3 years and 11 weeks) was noted. Disease progresses quickly and overall survival is poor, measured in weeks (2.5-16 weeks) from the diagnosis of leptomeningeal involvement. Four of our patients initiated whole-brain radiation therapy with only two completing the course prior to clinical deterioration. Our patient with the longest survival (16 weeks) received intrathecal topotecan and oral temozolomide. Leptomeningeal carcinomatosis secondary to esophageal cancer has a poor prognosis. A clearly beneficial treatment modality is lacking.
© 2014 International Society for Diseases of the Esophagus.

Entities:  

Keywords:  carcinomatous meningitis; cerebrospinal fluid; esophageal neoplasms; leptomeningeal carcinomatosis; meningeal carcinomatosis

Mesh:

Year:  2014        PMID: 25142531     DOI: 10.1111/dote.12276

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  8 in total

1.  A Fulminant Case of Leptomeningeal Carcinomatosis Secondary to Esophageal Adenocarcinoma.

Authors:  Banu Tasci Fresko; Meltem Topalgokceli Selam; Hatice Tuzlali; Burcin Batman; Oktar Asoglu
Journal:  J Gastrointest Cancer       Date:  2016-03

Review 2.  Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review.

Authors:  Michele Ghidini; Fausto Petrelli; Jens Claus Hahne; Annamaria De Giorgi; Laura Toppo; Claudio Pizzo; Margherita Ratti; Sandro Barni; Rodolfo Passalacqua; Gianluca Tomasello
Journal:  Med Oncol       Date:  2017-03-18       Impact factor: 3.064

Review 3.  Malignant meningitis secondary to oesophageal adenocarcinoma presenting with sensorineural hearing loss: a series of three cases and discussion of the literature.

Authors:  Mark Adams; Carolynne Doherty; Anna O'Kane; Samuel Hall; Raeburn B Forbes; Brian Herron; Edward J McNaboe
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-08       Impact factor: 2.503

4.  A systematic review of craniospinal irradiation for leptomeningeal disease: past, present, and future.

Authors:  L Maillie; L R Salgado; S Lazarev
Journal:  Clin Transl Oncol       Date:  2021-04-21       Impact factor: 3.405

Review 5.  Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.

Authors:  Yolanda Piña; Sirisha Yadugiri; Debra N Yeboa; Sherise D Ferguson; Peter A Forsyth; Isabella C Glitza Oliva
Journal:  Curr Oncol Rep       Date:  2022-01-20       Impact factor: 5.075

Review 6.  Leptomeningeal disease: current diagnostic and therapeutic strategies.

Authors:  Gautam Nayar; Tiffany Ejikeme; Pakawat Chongsathidkiet; Aladine A Elsamadicy; Kimberly L Blackwell; Jeffrey M Clarke; Shivanand P Lad; Peter E Fecci
Journal:  Oncotarget       Date:  2017-08-16

7.  Radiotherapy in Leptomeningeal Disease: A Systematic Review of Randomized and Non-randomized Trials.

Authors:  Samantha M Buszek; Caroline Chung
Journal:  Front Oncol       Date:  2019-11-15       Impact factor: 6.244

8.  Syndrome of inappropriate antidiuretic hormone in a patient with leptomeningeal carcinomatosis.

Authors:  Roosevelt Boursiquot; Danielle Krol; Sameul Hanif; Javier Rojas; Maneesh Jain
Journal:  J Med Case Rep       Date:  2016-03-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.